Ratings H.PIO Co., Ltd.

Equities

End-of-day quote Korea S.E. Other stock markets 03:30:00 17/05/2024 am IST			5-day change	1st Jan Change
3,730 ^KRW	-0.13%		-6.16%	-4.36%

20/03	H.PIO Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Tranche Update on H.PIO Co., Ltd.'s Equity Buyback Plan announced on November 17, 2023.	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Thanks to a sound financial situation, the firm has significant leeway for investment.
The stock, which is currently worth 2024 to 590.63 times its sales, is clearly overvalued in comparison with peers.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company is not the most generous with respect to shareholders' compensation.
Revenue estimates are regularly revised downwards for the current and coming years.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
H.PIO CO., LTD.	-4.36%	11Cr		-
ZHEJIANG NHU COMPANY LTD.	+16.86%	847.6Cr		D+
BELLRING BRANDS, INC.	+6.26%	759.52Cr		C-
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+4.89%	638.54Cr		-
THE SIMPLY GOOD FOODS COMPANY	-5.46%	374.96Cr		B-
BYHEALTH CO., LTD	-6.58%	370.82Cr		D
XIAMEN KINGDOMWAY GROUP COMPANY	-3.55%	135.51Cr	-	-
HERBALIFE LTD.	-28.90%	110.76Cr		B+
SIRIO PHARMA CO., LTD.	+18.12%	102.38Cr		-
USANA HEALTH SCIENCES, INC.	-8.94%	92Cr		C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality